Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases

被引：41

作者：

Gargiulo, Simona ^{[1
]}

Gamba, Paola ^{[1
]}

Poli, Giuseppe ^{[1
]}

Leonarduzzi, Gabriella ^{[1
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy

来源：

CURRENT PHARMACEUTICAL DESIGN | 2014年 / 20卷 / 18期

关键词：

Metalloproteinases; metalloproteinase inhibitors; atherosclerosis; diabetes mellitus; neurodegenerative diseases; osteoarthritis; BLOOD-BRAIN-BARRIER; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; ALPHA CONVERTING-ENZYME; LOW-DENSITY-LIPOPROTEIN; AMYLOID PRECURSOR PROTEIN; FACTOR-KAPPA-B; INCREASES COLLAGEN CONTENT; ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN;

D O I：

10.2174/13816128113196660701

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Degradation of the extracellular matrix is an important feature of embryonic development, morphogenesis, angiogenesis, tissue repair and remodeling. It is precisely regulated under physiological conditions, but when dysregulated it becomes a cause of many diseases, including atherosclerosis, osteoarthritis, diabetic vascular complications, and neurodegeneration. Various types of proteinases are implicated in extracellular matrix degradation, but the major enzymes are considered to be metalloproteinases such as matrix metalloproteinases (MMPs) and disintegrin and metalloproteinase domain (ADAMs) that include ADAMs with a thrombospondin domain (ADAMTS). This review discusses involvement of the major metalloproteinases in some age-related chronic diseases, and examines what is currently known about the beneficial effects of their inhibitors, used as new therapeutic strategies for treating or preventing the development and progression of these diseases.

引用

页码：2993 / 3018

页数：26

共 503 条

[1]

Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease [J].